← Back to Screener
Neurogene, Inc. Common Stock (NGNE)
Price$27.74
Favorite Metrics
Price vs S&P 500 (26W)-16.56%
Price vs S&P 500 (4W)36.70%
Market Capitalization$433.74M
All Metrics
Book Value / Share (Quarterly)$17.10
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.06
Price vs S&P 500 (YTD)31.06%
EPS (TTM)$-3.16
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-3.16
EPS (Annual)$-4.24
ROI (Annual)-34.11%
Cash / Share (Quarterly)$17.37
ROA (Last FY)-31.31%
EBITD / Share (TTM)$-3.44
ROE (5Y Avg)-36.27%
Cash Flow / Share (Annual)$-5.06
P/B Ratio1.64x
P/B Ratio (Quarterly)1.20x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-51.05x
ROA (TTM)-23.25%
EPS Incl Extra (Annual)$-4.24
Current Ratio (Annual)16.56x
Quick Ratio (Quarterly)16.44x
3-Month Avg Trading Volume0.17M
52-Week Price Return158.59%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)468.91x
Asset Turnover (Annual)0.00x
52-Week High$37.27
EPS Excl Extra (Annual)$-4.24
CapEx CAGR (5Y)-11.82%
26-Week Price Return-7.81%
Quick Ratio (Annual)16.44x
13-Week Price Return48.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.56x
Enterprise Value$329.918
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-8123.68%
Cash / Share (Annual)$17.37
3-Month Return Std Dev90.02%
Net Income / Employee (TTM)$-1
ROE (Last FY)-34.11%
Net Interest Coverage (Annual)-533.55x
EPS Basic Excl Extra (Annual)$-4.24
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)0.00x
ROI (TTM)-25.27%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)123.49%
Year-to-Date Return35.19%
5-Day Price Return44.45%
EPS Normalized (Annual)$-4.24
ROA (5Y Avg)-31.36%
Net Profit Margin (Annual)-8123.68%
Month-to-Date Return38.14%
EBITD / Share (Annual)$-4.64
Operating Margin (Annual)-8930.27%
LT Debt / Equity (Annual)0.25x
ROI (5Y Avg)-36.21%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.16
P/B Ratio (Annual)1.20x
Book Value / Share (Annual)$17.10
Price vs S&P 500 (13W)45.27%
Beta1.74x
Revenue / Share (TTM)$0.00
ROE (TTM)-25.27%
52-Week Low$10.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.29
4.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NGNENeurogene, Inc. Common Stock | — | — | — | — | $27.74 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases with limited treatment options. The company leverages its proprietary EXACT platform, which enables precise control of transgene expression to overcome disease-causing genetic mutations. Its pipeline includes NGN-401 for Rett syndrome and NGN-101, an AAV9-delivered gene therapy for CLN5 Batten disease.